Suzanne Blanchard, NP
Primary Care · Prudenville, MINPI 1023015104
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novo Nordisk at 34.0% of the total.
Across 118 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$680
- Lilly USA, LLC$397
- AstraZeneca$283
- Amgen$225
- GSK$131
- AbbVie$95
- plus $191 from 11 others
What the payments were for
- Food & beverage$1,94397%
- Education$583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $680 |
| Lilly USA, LLC | 27 | $397 |
| AstraZeneca | 15 | $283 |
| Amgen | 13 | $225 |
| GSK | 8 | $131 |
| AbbVie | 5 | $95 |
| Exact Sciences | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Pfizer | 1 | $17 |
| Bayer | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $11 |
How this compares
$2,001 in reported general payments places this provider in the 80th percentile of 292 primary care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 185 | $192,861 |
| OzempicSemaglutide | 91 | $123,077 |
| JardianceEmpagliflozin | 78 | $109,342 |
| EliquisApixaban | 50 | $58,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $58,095 |
| TrulicityDulaglutide | 31 | $46,471 |
| FarxigaDapagliflozin Propanediol | 55 | $43,234 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $16,832 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,441 |
| Buprenorphine | 17 | $6,357 |
| Rosuvastatin Calcium | 295 | $5,540 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 57 | $3,938 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,696 |
| Vilazodone Hcl | 12 | $3,161 |
| Levothyroxine Sodium | 262 | $3,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $397 | $239,332216 claims |
| Novo NordiskOzempic | $680 | $123,07791 claims |
| Boehringer IngelheimJardiance | $15 | $109,34278 claims |
| PfizerEliquis | $17 | $58,76750 claims |
| GSKTrelegy Ellipta | $131 | $58,09546 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $283 | $50,67667 claims |
| AbbVieArmour Thyroid | $95 | $2,60731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 292 primary care providers in Michigan.
Other primary care in Prudenville
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Rachel HetznerMadison Heights$8K
- Katherine HouleMarquette$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.